Silverback Therapeutics Inc (NASDAQ:SBTX) Price has made a new low but reversed it by closing above 9.10 again. There was clearly more buying than selling on Friday. Company has a good pipeline, cash on hand and a great CEO with huge experience (she led Synthorix into its acquisition by Sanofit). According to analysts' consensus price target of $51.80, Silverback Therapeutics has a forecasted upside of 452.2%. I have been accumulating this stock.